Cellectar to restate financial statements, receives Nasdaq delinquency notice for late Q2 filing

Cellectar Biosciences, Inc.

Restating audited FY2022 & FY2023 and unaudited Q1-Q3 2023 & Q1 2024 due to warrant accounting error in Oct 2022 financing.
Changes are non-cash and non-operating; restatement expected to take ~6 weeks before filing Q2 2024 10-Q.
Received Nasdaq notice on Aug 20, 2024 for late Q2 10-Q; must submit compliance plan by Oct 21, 2024.
Nasdaq may grant up to 180-day extension (until Feb 17, 2025) if plan accepted; otherwise can appeal.
No immediate delisting impact, but failure to regain compliance could lead to listing suspension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.